Overview

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.

Phase:

Phase 2

Details

Lead Sponsor:

Ironwood Pharmaceuticals, Inc.

Treatments:

Linaclotide